Conservative treatment with plasma rich in growth factors-Endoret for osteoradionecrosis

Giorgia Gallesio, Massimo Del Fabbro, Renato Pol, Carmen Mortellaro, Marco Mozzati

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: Osteoradionecrosis (ORN) is the worst long-term complication due to radiotherapy to the head and neck and is defined as an area of exposed necrotic oral bone, with failure to heal for at least 3 months. In most cases, ORN is associated with oral surgery procedures involving the jaw bone. The aim of this study was to evaluate the safety and effectiveness of a biological approach for ORN treatment.

METHODS: A series of 10 patients with ORN were treated by debridement of necrotic bone using an ultrasound device followed by application of plasma rich in growth factors (PGRF)-Endoret to improve and accelerate soft-tissue healing. Patients were followed clinically and radiographically up to 12 months. Pain was assessed in the first week postsurgery using a visual analogue scale (VAS). Maturation and quality of tissue healing was assessed using a modified healing index.

RESULTS: All cases were successfully treated. No intraoperative or postoperative complications occurred. Clinical and radiographic evaluations showed no signs of persistent infection or exposed bone up to 12 months of follow-up. The maturity and quality of the regenerated tissues was excellent, surgical wounds always achieving complete closure. VAS scores and trismus were very low in all patients, which did not take analgesics since the third day after surgery.

CONCLUSIONS: PRGF-Endoret is beneficial, as an adjunct to surgical treatment of osteoradionecrosis, for predictable enhancement of tissue vascularization and epithelialization in patients with a history of head and neck radiotherapy.

Original languageEnglish
Pages (from-to)731-736
Number of pages6
JournalJournal of Craniofacial Surgery
Volume26
Issue number3
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Osteoradionecrosis
Intercellular Signaling Peptides and Proteins
Bone and Bones
Visual Analog Scale
Neck
Radiotherapy
Head
Trismus
Oral Surgery
Intraoperative Complications
Debridement
Jaw
Ambulatory Surgical Procedures
Analgesics
Conservative Treatment
Safety
Pain
Equipment and Supplies
Therapeutics
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Conservative treatment with plasma rich in growth factors-Endoret for osteoradionecrosis. / Gallesio, Giorgia; Del Fabbro, Massimo; Pol, Renato; Mortellaro, Carmen; Mozzati, Marco.

In: Journal of Craniofacial Surgery, Vol. 26, No. 3, 01.05.2015, p. 731-736.

Research output: Contribution to journalArticle

Gallesio, Giorgia ; Del Fabbro, Massimo ; Pol, Renato ; Mortellaro, Carmen ; Mozzati, Marco. / Conservative treatment with plasma rich in growth factors-Endoret for osteoradionecrosis. In: Journal of Craniofacial Surgery. 2015 ; Vol. 26, No. 3. pp. 731-736.
@article{3d632dffe5dd47daaa762b477a8eeb51,
title = "Conservative treatment with plasma rich in growth factors-Endoret for osteoradionecrosis",
abstract = "OBJECTIVES: Osteoradionecrosis (ORN) is the worst long-term complication due to radiotherapy to the head and neck and is defined as an area of exposed necrotic oral bone, with failure to heal for at least 3 months. In most cases, ORN is associated with oral surgery procedures involving the jaw bone. The aim of this study was to evaluate the safety and effectiveness of a biological approach for ORN treatment.METHODS: A series of 10 patients with ORN were treated by debridement of necrotic bone using an ultrasound device followed by application of plasma rich in growth factors (PGRF)-Endoret to improve and accelerate soft-tissue healing. Patients were followed clinically and radiographically up to 12 months. Pain was assessed in the first week postsurgery using a visual analogue scale (VAS). Maturation and quality of tissue healing was assessed using a modified healing index.RESULTS: All cases were successfully treated. No intraoperative or postoperative complications occurred. Clinical and radiographic evaluations showed no signs of persistent infection or exposed bone up to 12 months of follow-up. The maturity and quality of the regenerated tissues was excellent, surgical wounds always achieving complete closure. VAS scores and trismus were very low in all patients, which did not take analgesics since the third day after surgery.CONCLUSIONS: PRGF-Endoret is beneficial, as an adjunct to surgical treatment of osteoradionecrosis, for predictable enhancement of tissue vascularization and epithelialization in patients with a history of head and neck radiotherapy.",
author = "Giorgia Gallesio and {Del Fabbro}, Massimo and Renato Pol and Carmen Mortellaro and Marco Mozzati",
year = "2015",
month = "5",
day = "1",
doi = "10.1097/SCS.0000000000001537",
language = "English",
volume = "26",
pages = "731--736",
journal = "Journal of Craniofacial Surgery",
issn = "1049-2275",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Conservative treatment with plasma rich in growth factors-Endoret for osteoradionecrosis

AU - Gallesio, Giorgia

AU - Del Fabbro, Massimo

AU - Pol, Renato

AU - Mortellaro, Carmen

AU - Mozzati, Marco

PY - 2015/5/1

Y1 - 2015/5/1

N2 - OBJECTIVES: Osteoradionecrosis (ORN) is the worst long-term complication due to radiotherapy to the head and neck and is defined as an area of exposed necrotic oral bone, with failure to heal for at least 3 months. In most cases, ORN is associated with oral surgery procedures involving the jaw bone. The aim of this study was to evaluate the safety and effectiveness of a biological approach for ORN treatment.METHODS: A series of 10 patients with ORN were treated by debridement of necrotic bone using an ultrasound device followed by application of plasma rich in growth factors (PGRF)-Endoret to improve and accelerate soft-tissue healing. Patients were followed clinically and radiographically up to 12 months. Pain was assessed in the first week postsurgery using a visual analogue scale (VAS). Maturation and quality of tissue healing was assessed using a modified healing index.RESULTS: All cases were successfully treated. No intraoperative or postoperative complications occurred. Clinical and radiographic evaluations showed no signs of persistent infection or exposed bone up to 12 months of follow-up. The maturity and quality of the regenerated tissues was excellent, surgical wounds always achieving complete closure. VAS scores and trismus were very low in all patients, which did not take analgesics since the third day after surgery.CONCLUSIONS: PRGF-Endoret is beneficial, as an adjunct to surgical treatment of osteoradionecrosis, for predictable enhancement of tissue vascularization and epithelialization in patients with a history of head and neck radiotherapy.

AB - OBJECTIVES: Osteoradionecrosis (ORN) is the worst long-term complication due to radiotherapy to the head and neck and is defined as an area of exposed necrotic oral bone, with failure to heal for at least 3 months. In most cases, ORN is associated with oral surgery procedures involving the jaw bone. The aim of this study was to evaluate the safety and effectiveness of a biological approach for ORN treatment.METHODS: A series of 10 patients with ORN were treated by debridement of necrotic bone using an ultrasound device followed by application of plasma rich in growth factors (PGRF)-Endoret to improve and accelerate soft-tissue healing. Patients were followed clinically and radiographically up to 12 months. Pain was assessed in the first week postsurgery using a visual analogue scale (VAS). Maturation and quality of tissue healing was assessed using a modified healing index.RESULTS: All cases were successfully treated. No intraoperative or postoperative complications occurred. Clinical and radiographic evaluations showed no signs of persistent infection or exposed bone up to 12 months of follow-up. The maturity and quality of the regenerated tissues was excellent, surgical wounds always achieving complete closure. VAS scores and trismus were very low in all patients, which did not take analgesics since the third day after surgery.CONCLUSIONS: PRGF-Endoret is beneficial, as an adjunct to surgical treatment of osteoradionecrosis, for predictable enhancement of tissue vascularization and epithelialization in patients with a history of head and neck radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84953344621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953344621&partnerID=8YFLogxK

U2 - 10.1097/SCS.0000000000001537

DO - 10.1097/SCS.0000000000001537

M3 - Article

C2 - 25974781

AN - SCOPUS:84953344621

VL - 26

SP - 731

EP - 736

JO - Journal of Craniofacial Surgery

JF - Journal of Craniofacial Surgery

SN - 1049-2275

IS - 3

ER -